Asunaprevir (formerly BMS-650032, brand name in Japan and Russia[1] Sunvepra) is an experimental drug candidate for the treatment of hepatitis C. It was undergoing development by Bristol-Myers Squibb and has completed Phase III clinical trials in 2013.

[2] Asunaprevir is an inhibitor of the hepatitis C virus enzyme serine protease NS3.

[3] Asunaprevir is being tested in combination with pegylated interferon and ribavirin, as well as in interferon-free regimens with other direct-acting antiviral agents including daclatasvir.

This antiinfective drug article is a stub.

You can help Wikipedia by expanding it.